Clinical • Enrollment open • Trial initiation date • Combination therapy • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • gemcitabine • SMT-NK